Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Dr. Reddy's Laboratories wins India approval for generic oral semaglutide (GLP-1) tablets for type-2 diabetes mellitus
Small molecule, metabolic, GLP-1 receptor agonist, type 2 diabetes, semaglutide, generic drug - Read more

Bavarian Nordic's VIMKUNYA (recombinant, adsorbed) receives Swissmedic approval for chikungunya virus prevention in individuals aged 12 and above
Vaccine, infectious disease, virus-like particle, chikungunya, recombinant protein vaccine - Read more

Aligos Therapeutics, Amoytop ink $445M deal licensing HBV drug pevifoscorvir sodium China rights
Licensing deal, infectious disease, small molecule, milestone payments, royalties - Read more

Faron Pharmaceuticals, Parexel collaborate on Phase IIb BEXERA trial for HR-MDS
Research collaboration, oncology, rare disease, antibody - Read more

Interna Therapeutics, Daiichi Sankyo collaborate on MNM-based intracellular delivery for targeted therapeutics
Research collaboration, drug delivery, nucleic acids, preclinical - Read more

MeiraGTx reacquires bota-vec gene therapy from J&J for $25M upfront plus milestone, royalties
Licensing deal, rare disease, gene therapy, ophthalmology, milestone payments, royalties - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Eli Lilly's Foundayo Ph3 data shows cardiovascular benefit, no liver safety signals in type 2 diabetes
Small molecule, metabolic, GLP-1 agonist, type 2 diabetes, cardiovascular outcomes, obesity - Read more

Freya Biosciences' FB301 (multi-strain Lactobacillus consortium) meets all Ph1 endpoints for in vitro fertilization-related embryo implantation failure
Protein therapy, reproductive health, microbiome therapy, IVF implantation failure, lactobacillus consortium, vaginal dysbiosis - Read more

STORM Therapeutics raises $56M Series C to advance oral METTL3 inhibitor for sarcoma
Oncology, small molecule, sarcoma, clinical-stage, epigenetics - Read more

Kailera Therapeutics prices massive $625M IPO for advancing next-generation obesity care treatments
Obesity, clinical-stage, small molecule, metabolic disease - Read more

Adlai Nortye plans $150M private placement to advance RAS-targeting cancer therapies
Oncology, clinical-stage, small molecule, ADC, RAS-targeting - Read more

Trevi Therapeutics prices $150M public offering, developing chronic cough treatments for lung diseases
Clinical-stage, small molecule, chronic cough, respiratory disease - Read more

Enveric Biosciences plans $13.9M private placement for product development and general purposes
Neurological, small molecule, psychiatric disorders, preclinical - Read more

RyghtAI launches RyghtSites.com search engine to streamline clinical trial site selection for drug developers
AI/machine learning, clinical trials optimization, operational, cost reduction - Read more

Qiagen launches QIAstat-Dx BCID GPF Plus AMR panel, expanding into bloodstream infection diagnostics
Diagnostics, infectious disease, strategic, financial - Read more

OpenAI launches GPT-Rosalind reasoning model for drug discovery with Amgen, Moderna, Thermo Fisher Scientific
Research collaboration, AI/ML, drug discovery, biologics, multi-omics - Read more

NICE recommends GSK's Blenrep for relapsed multiple myeloma, opening NHS access to 1,600 patients annually
Antibody-drug conjugate, multiple myeloma, regulatory, revenue impact - Read more

Roche launches new Phase III study to pursue EU approval for DMD gene therapy Elevidys
Gene therapy, rare disease, regulatory, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Early-stage biotech funding hits post-pandemic low in Q1 2026, as investors favor later-stage companies
Venture capital, early-stage funding, financial, strategic - Read more

Trump nominates Erica Schwartz, ex-deputy surgeon general, as next CDC director
Vaccines, infectious disease, regulatory, operational - Read more

Viatris, Teva Pharmaceutical Industries launch separate U.S. recalls over dissolution, unapproved raw material issues
Small molecule, cardiovascular, operational, regulatory - Read more

ICER calls for greater FDA transparency in accelerated approval program decisions and processes
Accelerated approval, oncology, regulatory, transparency - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here